Silexion Therapeutics Corp Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.09 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.28Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $1.6M Enterprise Value $1.3M Shares Outstanding 5.6M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Silexion Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) therapies for KRAS-driven cancers, specifically targeting locally advanced pancreatic cancer (LAPC). The company's lead candidate, SIL204, is poised to enter a Phase 2/3 clinical trial in Israel and Europe, supported by positive regulatory feedback and preclinical safety data. While Silexion is a pre-revenue micro-cap with significant cash burn and dilution risks, its unique localized drug-delivery platform and the high unmet medical need in pancreatic oncology present a high-upside opportunity for risk-tolerant investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$60.00 Mean target$60.00 High · most bullish analyst$60.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.5020% The Phase 2/3 trial of SIL204 faces regulatory or enrollment delays in Europe. Shareholders reject the capital proposals at the July 13, 2026 meeting, leading to Nasdaq delisting due to failure to maintain shareholders' equity or minimum bid price requirements. The company is forced to seek highly dilutive over-the-counter financing, severely depressing share value. Base CaseCentral scenario $6.0050% Silexion successfully initiates the Phase 2/3 trial of SIL204 in Israel and Germany. Shareholders approve the capital proposals at the July 13, 2026 meeting, allowing the company to maintain its Nasdaq listing and utilize its ATM facility and warrant exercises to fund operations. The company continues as a clinical-stage developer with gradual pipeline progress, in line with consensus analyst expectations. Bull CaseUpside scenario $6.0030% SIL204 successfully initiates its Phase 2/3 trial in Q2/Q3 2026, showing strong safety in the run-in cohort and early efficacy signals. The company secures a major global pharmaceutical partnership at the BIO International Convention or shortly after, providing non-dilutive funding and validating its localized RNAi platform. Shareholders approve the capital proposals on July 13, 2026, restoring long-term Nasdaq compliance and providing a clear runway. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |